Skip to main content

Table 4 Mutations of EGFR, HER2 and their transducers found in samples from patients.

From: Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas

Sample EGFR KRAS
exon 2
PI3K
exon 9
PI3K
exon 20
BRAF
exon 15
PTEN
1 WT WT WT WT WT WT
2 WT WT WT WT WT WT
3 WT WT WT WT WT WT
4 WT WT WT WT WT WT
5 WT WT WT WT WT WT
6 WT WT WT WT WT WT
7 WT WT WT WT WT WT
8 WT WT WT WT WT WT
9 WT WT WT WT WT WT
10 WT WT WT WT WT WT
11 WT WT WT WT WT WT
12 WT WT WT WT WT WT
13 WT WT WT WT WT WT
14 WT WT WT WT WT WT
15 WT WT WT WT WT WT
16 WT WT WT WT WT WT
17 WT WT WT WT WT WT
18 WT WT WT WT WT WT
19 WT WT WT WT WT WT
20 WT WT WT WT WT WT
21 K757R WT WT WT WT WT
22 WT G13D WT WT V600E WT
23 WT G13D E545K H1047R WT T202I/E235G
24 WT WT WT WT WT WT
25 WT WT WT WT V600E WT
26 C775Y WT WT WT WT WT
27 WT WT WT WT WT WT
28 WT WT WT WT WT WT
29 V843I WT Q546L WT WT F271L
30 WT WT WT WT WT WT
31 E872K WT E545A WT V600E WT
32 WT WT WT WT WT WT
33 WT WT WT WT WT WT
34 WT WT WT WT WT WT
35 WT WT WT WT WT WT
36 T790M WT WT WT WT WT
37 WT WT WT WT WT WT
38 WT WT WT WT WT WT
39 W817STOP WT WT WT WT WT
40 WT WT WT WT WT WT
41 WT WT WT WT WT WT
42 WT WT WT F1059L WT WT
43 WT WT WT WT V600E WT
44 WT I24F WT WT WT WT
45 A864T WT WT WT WT WT
46 WT WT WT WT WT WT
47 WT WT WT WT WT WT
48 WT WT WT WT WT WT
49 WT WT WT WT WT WT
  1. WT: wild type.